Sign Up | Log In | What is SocialPicks?

Free Stock Picks by Top Performers

SocialPicks is a community where stock investors exchange ideas and track performance of financial bloggers.

Are you a stock guru?

Share picks & earn reputation

Mike Havrilla www.BioRunUp.com

Start Tracking Mike Havrilla - Add to Friends - Send Message

Community Rank: Principal (7000 pts) | Member since 07/15/2008

Picks Performance:

Outperforms

73%

of community

What's this?

All-time Return +1.04% (in over 4 years)	Risk (SD) Moderate 0.00%	Sharpe Ratio -2.09
Followers 87	Winning Picks 786 of 1807	Total Views 2575711

Overview

Stocks

Stats

Community

Widget

Last Activity: Added AMRN to bullish list on 11/29/10

Current Stock List:

Symbol	SP Sentiment	Return	Since
AMRN		+20.64%	11/29/10
IBB		+96.56%	11/22/10
EXAS		+71.79%	10/21/10
BIOD		-0.24%	10/17/10
LCI	N/A	+141.45%	10/06/10
QCOR		-340.31%	08/19/10
BMOD	N/A	n/a	08/09/10
ALXA		+82.80%	08/05/10
AGN		+57.51%	08/03/10
IRIS	N/A	n/a	08/02/10

All-time Sectors of Interest

... View All >

Opinion & Analysis

BioRunUp's Pick of AMRN up 130% / Now Offering New .. about AMRN 11/29/10
In celebration of our pick, AMRN, surging over 130% since our first mention we are offering a new re-occurring monthly plan for new subscribers, priced at only $49.95 a month. This plan is...

BioRunUp Mobile App Launches on iTunes, New Feature.. about IBB 11/22/10
The BioRunUp application is the mobile companion to BioRunUp.com, which is the best resource on the Internet for making consistent, risk-mitigated gains trading bio-pharmaceutical stocks ahead of regul...

Detecting More Upside Potential for EXACT Sciences .. about EXAS 10/21/10
With shares of EXACT Sciences (NASDAQ:EXAS) pulling back from multi-year highs in the low $9s back to the low-mid $7s as I write this article, I am adding to my long stock position ahead of the validat...

BioRunUp / mikehavRx Merger: More Resources to Prof.. about IBB 10/17/10
We are extremely excited to announce the launch of an all new BioRunUp.com paid subscription service , which includes a merger with mikehav...

BioRunUp / mikehavRx Merger: More Resources to Prof.. about BIOD 10/17/10
 We are extremely excited to announce the launch of an all new &l...

... View All >

Blog Posts

MM ONTY Oncothyreon (ONTY) Research Note 03/18/09 — Visit the BioMedReports.com research section to view or download the PDF for Cougar Biotechnology (CGRB) along with other free PDF reports and corporate investor presentations:http://biomedreports.com/research.htmlOncothyreon (ONTY): Price: $1.21; Market Cap (MM): $23.6Market Outperform; Target Price...

Read 17 comments

MM CGRB Cougar Biotech Research Note 03/17/09 — Visit the BioMedReports.com research section to view or download the PDF for Cougar Biotechnology (CGRB) along with other free PDF reports and corporate investor presentations:http://biomedreports.com/research.htmlCGRB: Price: $28.46; Market Cap (MM): $590.1Market Outperform; Target Price: $36.00Simo...

Read 58 comments

DRRX UTHR Updated Clinical Trial and FDA Calendars 03/17/09 — Below is a summary of updates to the www.BioMedReports.com database of 243 entries included in the FDA and Clinical Trial Calendars.http://biomedreports.com/fda-calendar.html The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FD...

Read 120 comments

MM SNTA Synta Pharma Proceeds with Clinical Trial 03/17/09 — Visit the BioMedReports.com research section to view or download the PDF for Synta Pharma (SNTA) along with other free PDF reports and presentations:http://biomedreports.com/research.htmlSynta Pharma: Price: $1.94; Market Cap (MM): $65.8Market Perform; Simos Simeonidis, Ph.D. - Senior Biotech Analyst...

Read 23 comments

MM PARD Poniard Pharma Awaits Key Cancer Drug Data 03/17/09 — Visit the BioMedReports.com research section to view or download the six page PDF for Poniard Pharma (PARD) along with other free PDF reports and presentations:http://biomedreports.com/research.htmlPARD: Price: $1.87; Market Cap (MM): $64.9Market Outperform; Target Price: $10.00Simos Simeonidis, Ph.D...

Read 10 comments

... View All >

Discussions

Mike Havrilla hasn't participated in any discussions yet.

People Following Mike Havrilla ...

Mathieu Godbout Paquet

Principal

73%

mbmalone

Analyst

N/A

Ahmed El Alfy

Analyst

N/A

... View All >

Mike Havrilla is Following ...

Mathieu Godbout Paquet

Principal

73%

Greg

Associate

73%

Jeremy McDonald

Associate

76%

... View All >

Friends of Mike Havrilla ...

Greg

Associate

73%

sivoodoo

Analyst

N/A

charmed

Analyst

N/A

... View All >

Similarity to Me ?

Compare Your Portfolio With Mike Havrilla: Enter stocks you like & track your performance:

Symbols, separated by space (e.g. AAPL GOOG MSFT)

More about Mike Havrilla

Investment Style:
Aggressive [?]

Avg exp holding time:
384.29 days

Age: 30's
Location: USA

Website:
www.BioRunUp.com

About Me:

I am a pharmacist, writer, marathon runner, and investor. Check out the Ultimate Guide to Biotech Sto ... more

Similar Portfolios

Marian Filo (supratrade) 62% 67%

Art (unicomtrade.com) N/A 31%

Statistician (optimist) N/A 31%

Steven Halpern (trackstevenhalpern_bloggingstocks) 56% 25%

supratrader (supratrader) N/A 21%

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.